CDA | Evidence Driven
CDA | Evidence Driven

teprotumumab

Details

Generic Name:
teprotumumab
Project Status:
Pending
Therapeutic Area:
Thyroid Eye Disease (TED), chronic
Manufacturer:
Amgen Canada Inc.
Call for patient/clinician input open:
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
SR0853-001
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Teprotumumab is indicated in adults for the treatment of moderate to severe Thyroid Eye Disease (TED).
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
Teprotumumab is indicated in adults for the treatment of moderate to severe Thyroid Eye Disease (TED).
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Last Updated : September 12, 2024